Harvard School of Public Health (HSPH)

hsph.harvard.edu

Total trials

153

Active

19

Phase 3

20

Total enrollment

2,493,770

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 5 of 5 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
DTG/ABC/3TC1
Kaletra1
Lamivudine1
Zidovudine1
Nevirapine2

Next readouts

  • 2020-11-06
  • 2026-05-31

Top conditions

  • HIV Infections12
  • Anemia11
  • Obesity8
  • HIV Infection8
  • Tobacco Use Cessation6
  • Cardiovascular Diseases6
  • Health Behavior5
  • Pregnancy5

Frequently asked questions about Harvard School of Public Health (HSPH)

How many clinical trials does Harvard School of Public Health (HSPH) have on ClinicalTrials.gov?
Harvard School of Public Health (HSPH) is listed as the lead sponsor on 153 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
How many of Harvard School of Public Health (HSPH)'s trials are in Phase 3?
20 of Harvard School of Public Health (HSPH)'s trials are in Phase 3, spread across 5 active drug programs.
What therapeutic areas does Harvard School of Public Health (HSPH) focus on?
Harvard School of Public Health (HSPH)'s most-studied conditions on ClinicalTrials.gov are HIV Infections, Anemia, Obesity, HIV Infection, Tobacco Use Cessation.
When are Harvard School of Public Health (HSPH)'s next clinical trial readouts?
Harvard School of Public Health (HSPH) has 2 upcoming primary-completion readouts tracked here; the soonest is “Early Infant HIV Treatment in Botswana”, expected around 2020-11-06.